Related Experiment Video
Updated: Mar 9, 2026
Routine Screening Method for Microparticles in Platelet Transfusions
Published on: January 31, 2018
Differences in levels of platelet-derived microparticles in platelet components prepared using the platelet rich
Egarit Noulsri1, Prapaporn Udomwinijsilp2, Surada Lerdwana3
1Research Division, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Background:
There has been an increased interest in platelet-derived microparticles (PMPs) in transfusion medicine. Little is known about PMP status during the preparation of platelet concentrates for transfusion.
Aim:
The aim of this study is to compare the PMP levels in platelet components prepared using the buffy coat (BC), platelet-rich plasma platelet concentrate (PRP-PC), and apheresis (AP) processes.
Methods:
Platelet components were prepared using the PRP-PC and BC processes. Apheresis platelets were prepared using the Trima Accel and Amicus instruments. The samples were incubated with annexin A5-FITC, CD41-PE, and CD62P-APC. At day 1 after processing, the PMPs and activated platelets were determined using flow cytometry.
Results:
Both the percentage and number of PMPs were higher in platelet components prepared using the Amicus instrument (2.6±1.8, 32802±19036 particles/μL) than in platelet components prepared using the Trima Accel instrument (0.5±0.4, 7568±5298 particles/μL), BC (1.2±0.6, 12,920±6426 particles/μL), and PRP-PC (0.9±0.6, 10731±5514 particles/μL). Both the percentage and number of activated platelets were higher in platelet components prepared using the Amicus instrument (33.2±13.9, 427553±196965 cells/μL) than in platelet components prepared using the Trima Accel instrument (16.2±6.1, 211209±87706 cells/μL), BC (12.9±3.2, 140624±41003 cells/μL), and PRP-PC (21.1±6.3, 265210±86257 cells/μL).
Conclusions:
The study suggests high variability of PMPs and activated platelets in platelet components prepared using different processes. This result may be important in validating the instruments involved in platelet blood collection and processing.
Insights
Platelet-derived microparticles (PMPs) and activated platelets vary significantly across different preparation methods. The Amicus apheresis system yielded higher levels of both PMPs and activated platelets compared to other methods.
Area of Science:
- Transfusion Medicine
- Hematology
- Biotechnology
Background:
- Platelet-derived microparticles (PMPs) are gaining attention in transfusion medicine.
- Understanding PMP levels during platelet concentrate preparation is crucial but limited.
- This study investigates PMP status across various platelet processing techniques.
Purpose of the Study:
- To compare platelet-derived microparticle (PMP) levels in platelet components prepared by buffy coat (BC), platelet-rich plasma platelet concentrate (PRP-PC), and apheresis (AP) methods.
- To evaluate the impact of different apheresis instruments (Amicus and Trima Accel) on PMP and activated platelet levels.
Main Methods:
- Platelet components were prepared using PRP-PC and BC methods.
- Apheresis platelets were collected using Trima Accel and Amicus instruments.
- Flow cytometry, utilizing annexin A5-FITC, CD41-PE, and CD62P-APC, was employed to quantify PMPs and activated platelets one day post-processing.
Main Results:
- The Amicus instrument produced significantly higher percentages and numbers of PMPs compared to Trima Accel, BC, and PRP-PC methods.
- Similarly, the Amicus instrument resulted in higher percentages and numbers of activated platelets than the other tested methods.
- Specific particle/cell counts for PMPs and activated platelets were detailed for each preparation method.
Conclusions:
- Significant variability in PMP and activated platelet levels exists among different platelet preparation processes.
- These findings highlight the importance of instrument validation in platelet collection and processing for transfusion.
- The results suggest that the choice of preparation method and instrument can influence PMP and activated platelet content in platelet concentrates.
More Related Videos
05:49Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
Published on: November 29, 2024
08:34Production of Autologous Platelet-Rich Plasma for Boosting In Vitro Human Fibroblast Expansion
Published on: February 24, 2021
